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is maximum likelihood estimate of the parameter values. The log-likelihood 3 9 4
ratio follows a chi-square distribution:
is the chi-square statistic of the lead variant and r is the correlation coefficient 3 9 6
between the two variants. Because of the additive property of the chi-square distribution,
logBF follows a non-central chi-square distribution with 1 degree of freedom and non-3 9 8 centrality parameter
. Therefore, the power can calculated as the probability 3 9 9
that logBF > log(10), given by the CDF of the non-central chi-squared distribution. 
2 3
Intestine) and colon) and human cell lines using a custom made Agilent expression array. with missing data rate >2% across the whole dataset, or >10% in any one batch, and 4 9 9
variants that failed (FDR < 10 -5 in either the whole dataset or at least two batches) tests mapping analysis.
3 0
Manual cluster plot inspection 5 3 1
Variants that had posterior probability greater than 50% or in credible sets mapped to ≤ 5 3 2 10 variants were manually inspected using Evoker v2.2 42 . Each variant was inspected by 5 3 3 3 independent reviewers (10 reviewers participated) and scored as pass, fail or maybe.
3 4
We remove variants that received one or more fails, or received less than 2 passes. 650
out of 905 inspected variants passed this inspection. A further cluster plot inspection 5 3 6
flagged two additional failed variants after removing the failed variants from the first 5 3 7
inspection and redoing the imputation and analysis.
3 8
Establishing a p-value threshold 5 3 9
We used a multiple testing corrected p-value threshold for associations of 10 -6 , which was 
4 9
Detecting and fine-mapping association signals 5 5 0
We used three fine-mapping methods to detect independent signals and create credible between the associated-to-both model and the best of the single-phenotype associated 5 7 2 models.
7 3
Estimating the variance explained by the fine-mapping
7 4
We used a mixed model framework to estimate the total risk variance attributable to the 5 7 5
IBD risk loci, and to the signals identified in the fine-mapping. We the GCTA software done prior to fine-mapping), or (ii) the all signals identified in fine-mapping. We used
9 3
Cox and Snell's method 45 to estimate the variance explained across independent signals 5 9 4
(Extended Data Figure 2b ) for computational efficiency.
9 5
Overlap between transcription factor binding motifs and causal variants 5 9 6
For each motif in the ENCODE TF ChIP-seq data (http://compbio.mit.edu/encode- , where n is the size of the credible set and f is the proportion of all variants 6 0 3
in the high-density region that disrupt or a create a motif in that TF family.
0 4
Overlap between epigenetic signatures and causal variants 6 0 5
For each combination of 120 tissues and three histone marks (H3K4me1, H3K4me3 and 6 0 6
H3K27ac) from the Roadmap Epigenome Project we calculated an overlap score, equal 6 0 7
to the sum of fine-mapping posterior probabilities for all variants in peaks of that histone 6 0 8 mark in that tissue. We generated a null distribution of this score for each tissue/mark by 6 0 9
shifting chromatin marks randomly over the high-density regions (shifting the peaks 6 1 0 from their actual position by a random number of bases while keeping inter-peak spacing 6 1 1 the same) and calculating the overlap score for each permutation. To summarize these 6 1 2
correlated results across many cell and tissue types we defined a set of "core" H3K4me1 . We selected 6 immune cell types for H3K4me1 and 3 gut cell types for 6 1 6
H3K27ac (Supplementary Table 2 ). We also chose controls (Supplementary Table 2) 6 1 7
from non-immune and non-gut cell types with similar density of peaks in the fine-6 1 8 mapped regions as compared to immune/gut cell types to confirm the tissue-specificity of 6 1 9 the overlap. We used the phenotype assignments (described above) in dissecting the 6 2 0 enrichment for the CD and UC signals. Sixty-five CD and 21 UC signals were used in 6 2 1 this analysis.
2 2
Published eQTL summary statistics 6 2 3
We used eQTL summary statistics from two published studies: 6 2 4
• Peripheral blood eQTLs from the GODOT study 48 of 2,752 twins, reporting loci with 6 2 5
MAF>0.5%.
2 6
• CD14+ monocyte eQTLs from density regions (94 fine-mapped plus 3 unresolved) were retained for further analyses.
5 4
Naïve co-localization using lead SNPs 6 5 5
We calculated the proportion of IBD credible sets that contain a lead eQTL variant in a 6 5 6 particular tissue. This value is then compared to a background rate:
where ܰ is the total number of variants in region 
3
Frequentist co-localization using conditional p-values 6 6 4
We next used conditional association to test for evidence of co-localization, as described 6 6 5
in Nica et al.
25
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